retatrutide for diabetes type 2 Effects of on body composition in people with diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial Retatrutide—A Game Changer in Obesity

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormonal pathways involved in appetite regulation and blood sugar control

The SURPASS-4 clinical trial was a non-inferiority study comparing tirzepatide to insulin glargine where tirzepartide showed superior A1c and body weight reductions from baseline in adults with T2DM at increased CVD risk.[20] Also, tirzepatide reported a higher occurrence of individuals achieving an A1c below 7% compared to insulin glargine

Another critical advantage is appetite regulation without deprivation

Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic beta-cells